ClinicalTrials.gg
RecruitingNCT07368946PACKUpdated Jan 28, 2026

Phosphate Assessment in Chronic Kidney Disease Patients Study

An interventional study of Dietary Phosphorus Intake in Chronic Kidney Disease (Stage 3-4) and Chronic Kidney Disease Mineral and Bone Disorder, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled May 2025, registered Nov 2025).
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Renal Insufficiency, Chronic by University of Texas Southwestern Medical Center — 5 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · University of Texas Southwestern Medical Center.

Started
2025
the only one that year
No phase
5 of 11
3 open now
Registered
9th of 11
by date

Among the 11 studies in Renal Insufficiency, Chronic by University of Texas Southwestern Medical Center, this one is the only one that started in 2025, is one of 5 with no phase, and was the 9th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

5 of the 11 studies in Renal Insufficiency, Chronic by University of Texas Southwestern Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Renal Insufficiency, Chronic by University of Texas Southwestern Medical Center, or all of them as a file.
02

Study summary

The proposed pilot feeding study aims to explore novel pathways in phosphate metabolism and identify new biomarkers, as well as to develop a compound index for assessing phosphate overload with high validity and reliability.

Investigators will address the following specific aims: 1). To explore novel pathways of phosphate metabolism and assess the influence of CKD status on these metabolic pathways. 2). To identify novel biomarkers for phosphate overload that reflect changes in dietary phosphorus intake. 3). To develop a compound phosphate overload index that measures dietary phosphorus intake with high validity and reliability.

This study will provide novel insights into phosphate metabolism and the assessment of phosphate overload in CKD patients. This investigation aims to provide preliminary data to further studies for the development of reliable biomarkers in CKD patients, which could contribute significantly to early interventions and improve health outcomes.

Read the detailed description

Specifically, study team propose recruiting 30 participants with CKD and 30 without CKD to investigate the responses of blood metabolites and known biomarkers to a 21-day diet intervention. The intervention will consist of a dietary phosphorus intake of about 777 mg/day for 7 days, followed by an increase to about 1,277mg/day for another 7 days, and a further increase to about 1,777 mg/day for the subsequent 7 days. 1200 mg/day and 1700 mg/day phosphorus diets will be achieved by providing participants with sodium phosphate capsules and 777 mg/day meals. The meal plan will maintain consistent intake of calories, sodium, potassium, and calcium throughout the 21-day intervention. Sodium, calcium, and potassium content will not change significantly throughout the intervention. The overnight fasting blood and 24-hour and random urine samples will be collected at the baseline and end of each phase.

03

Conditions studied

  • Chronic Kidney Disease (Stage 3-4)
  • Chronic Kidney Disease Mineral and Bone Disorder

Keywords

  • chronic kidney disease
  • study diet
  • feeding study
  • pilot
  • oral phosphate feeding
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged 18 years or older, of any race/ethnicity
  • Women must either be or have no monthly menstrual cycle
  • Estimated total daily energy expenditure (TDEE) of 1700 - 2700 calories
  • >15 ml/min/1.73m2 - \< 60 ml/min/1.73m2 for the CKD group (CKD Stage 3 or Stage 4)
  • eGFR ≥ 60 ml/min/1.73m2 and negative urine protein on dipstick test for the non-CKD group
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • Pregnant, currently breastfeeding, or \<3 months postpartum
  • Current dialysis or kidney transplant patient
  • Current use of insulin or chemotherapy drugs
  • Smokes cigarettes or uses e-cigarettes (vapes)
  • Uses nicotine products or other recreational drugs
  • Medical history of stroke or myocardial infarction (MI)
  • Medical history of conditions that can affect phosphate metabolism (i.e., uncontrolled thyroid disorder, parathyroid disorder, or gastrointestinal malabsorption disorders [Crohn's, ulcerative colitis, and celiac disease], cirrhosis)
  • Current use of certain medications that directly alter phosphate levels (i.e., phosphate binders; phosphate supplements, irregular use of iron)
  • Regular use of laxatives
  • Hypo- or hyperphosphatemia (serum phosphate \< 2.5 or > 4.6 mg/dl)
  • Hypo- or hypercalcemia (serum calcium \< 8.4 or > 10.7 mg/dl)
  • Severe anemia ( \< 8 g/dl for women and \< 9 g/dl for men)
  • Severe hyperglycemia (serum blood glucose > 300 mg/dl)
  • Body weight less than \<110 lbs (due to risk for phlebotomy-induced anemia)
  • Received a blood transfusion in the last four months
  • Extreme hypertension as demonstrated by a blood pressure > 180/120 as the average of 3 blood pressures taken during the screening/baseline, or extremely low blood pressure \< 80/50
  • Unwilling or unable to eat study meals
  • Lack of access to a functional refrigerator or freezer
  • Lack of access to a microwave or conventional oven
  • On low potassium diet
  • On low phosphate diet
  • Specific dietary restrictions (i.e. vegetarian, vegan, ketogenic, etc.)
  • Food allergies including but not limited to milk, egg, soy, nuts, shellfish, and wheat or gluten
  • Allergic to sodium phosphate
  • Unable or unwilling to complete urinary sample collection or food diaries
  • Unable or unwilling to provide
  • Unable to read or speak English
  • Participant in other conflict clinical trial
  • Unable to complete the study measurements
  • Unsafe to participate in this study per investigator's judgement
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Chronic Kidney Disease Patients

    Participants with eGFR \>15 ml/min/1.73m2 - \< 60 ml/min/1.73m2 for the CKD group

    Dietary Supplement: Dietary Phosphorus Intake

  • Active comparator
    Control Group

    Healthy participants without CKD eGFR ≥ 60 ml/min/1.73m2

    Dietary Supplement: Dietary Phosphorus Intake

Interventions

  • Dietary supplementDietary Phosphorus Intake

    Dietary phosphorus intake of about 777 mg/day for 7 days, followed by an increase to about 1,277mg/day for another 7 days, and a further increase to about 1,777 mg/day for the subsequent 7 days. The meal plan will maintain consistent intake of calories, sodium, potassium, and calcium throughout the 21-day intervention. 1200 mg/day and 1700 mg/day phosphorus diets will be achieved by providing participants with sodium phosphate capsules and 777 mg/day meals.

06

What researchers measure

Primary outcomes

  1. Change in serum phosphate levels

    Circulating serum phosphate levels (mg/dL) will be measured using standard clinical laboratory assays

    Time frame: Baseline, week 1, week 2, and week 3

  2. Change in parathyroid hormone (PTH) levels

    Circulating PTH levels (pg/mL) will be measured using standard clinical laboratory assays

    Time frame: Baseline, week 1, week 2, and week 3

  3. Change in C-terminal Fibroblast Growth Factor 23 (FGF23) levels

    Circulating C-terminal FGF23 levels (RU/mL) will be measured using standard clinical laboratory assays

    Time frame: Baseline, week 1, week 2, and week 3

  4. Change in Fibroblast Growth Factor 23 (FGF23) levels

    Circulating FGF23 levels (pg/mL) will be measured using standard clinical laboratory assays

    Time frame: Baseline, week 1, week 2, and week 3

  5. Phosphate burden indices

    Phosphate burden indices, developed using machine learning methods to systematically incorporate both known biomarkers and novel biomarkers. No units have been identified, we anticipate creating a score.

    Time frame: Baseline, week 1, week 2, week 3

Secondary outcomes

  1. Change in serum calcium levels

    Circulating serum calcium levels (mg/dL) will be measured using standard clinical laboratory assays

    Time frame: Baseline, week 1, week 2, and week 3

  2. Change in Alkaline Phosphatase (ALP) levels

    Circulating serum ALP levels (U/L) will be measured using standard clinical laboratory assays

    Time frame: Baseline, week 1, week 2, and week 3

  3. Change in 1,25-dihydroxyvitamin D levels

    Circulating serum 1,25-dihydroxyvitamin D levels (pg/mL) will be measured using standard clinical laboratory assays

    Time frame: Baseline, week 1, week 2, and week 3

  4. Change in Bone-Specific Alkaline Phosphatase (BALP) levels

    Circulating serum BALP levels (U/L) will be measured using standard clinical laboratory assays

    Time frame: Baseline, week 1, week 2, and week 3

  5. Change in urinary calcium levels

    Circulating urinary calcium excretion levels (mg/day) will be measured using standardized laboratory urine assays

    Time frame: Baseline, week 1, week 2, and week 3

  6. Change in urinary phosphorus levels

    Circulating urinary phosphorus excretion levels (mg/day) will be measured using standardized laboratory urine assays

    Time frame: Baseline, week 1, week 2, and week 3

Other outcomes

  1. Exploratory: Phosphate-related biomarkers identified using proteomics platforms

    For the proteomics analysis, only novel biomarkers associated with the phosphate diet will be reported, and their quantitative values are expressed as relative fluorescence units (RFU).

    Time frame: Baseline, week 1, week 2, week 3

  2. Exploratory: Phosphate-related biomarkers identified using metabolomics platforms

    For the metabolomic analysis, only novel biomarkers associated with the phosphate diet will be reported. These features are not yet chemically identified, quantitative results are expressed as relative abundances.

    Time frame: Baseline, week 1, week 2, week 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — IRB approval is required before sharing IPD.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 19 months is below that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Jan 27, 2026
StartActual
May 9, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07368946
Responsible party
Jing Chen (Principal Investigator, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Jan 27, 2026
Start date
May 9, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 28, 2026

Study contacts

Alexandra Hartman
Contact
pack.utsw@utsouthwestern.edu
214-645-8294
Paola Lanza, MD
Contact
paola.lanza@utsouthwestern.edu
469-852-9550
Jing Chen, MD
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion